|Last Price$10.39||Day Change (%)-0.57%|
|Open Price$10.39||Day Change ($)-0.06|
|Day Range10.39–10.39||52-Week Range8.99–11.94|
As of Tue 10/25/2016 | USD
Paion AG: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting
We serve up the three CEFs on our coverage list with the highest Morningstar Analyst Rating.
The number of closed-end funds available has shrunk by nearly one fifth since 2011.
We take a closer look at the funds in our model portfolio of closed-end funds.
Despite high levels of volatility since its October inception, our Strategic Income Portfolio edged out its benchmark, but we are making some portfolio adjustments.
We look at the past three months and make some portfolio adjustments.
Our increased coverage includes new medalists.
Five offerings deemed to be right for right now.
Morningstar's Cara Esser breaks down our Analyst Ratings for closed-end funds and names the CEFs that are worthy of gold status.
A breakdown of the CEF team's analyst ratings by firm, analyst, and Morningstar classification.